TME Pharma Teams up with Aimed Analytics for AI-Powered Drug Discovery

TME Pharma N.V., a biotechnology firm in the clinical stage dedicated to creating innovative cancer therapies that target the tumor microenvironment (TME), revealed a partnership with aimed analytics, an advanced medical data analytics company. This collaboration seeks to utilize artificial intelligence (AI) to develop new and enhanced drug candidates without relying on labor-intensive laboratory testing that requires significant time and resources.

The partnership utilizes the latest innovative developments in AI to speed up schedules while lowering related expenses and the requirement for experimental facilities.

"The 2024 Nobel Prize in Chemistry was awarded for AI-based models that allow remarkable prediction of molecular structures. This technology can also be used to discover new drugs and improved versions of existing drugs. We believe that the collaboration with aimed analytics will further advance our strategic vision announced last December. By combining our expertise in development of oligonucleotide drugs, cancer biology and immune-oncology with aimed analytics' cutting-edge capabilities, we aim to integrate AI- and Deep Learning-driven insights into our drug discovery capabilities," said Aram Mangasarian, CEO of TME Pharma. 

"The goal of this collaboration is to allow TME Pharma to not only bring its existing drugs to the table for strategic partners, but also the potential for rapid and efficient discovery of new drugs. We are committed to delivering on the goals of our new strategy announced in December 2024 and plan to share further information about our progress in the coming weeks."